• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Isofol Medical

0.71 SEK

+5.03 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.03 %
-2.34 %
+12.70 %
-2.61 %
+1.43 %
-27.59 %
+48.80 %
-91.07 %
-94.73 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Read more
Market cap
227.55M SEK
Turnover
169.31K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/8
2026

Interim report Q2'26

12/11
2026

Interim report Q3'26

12/2
2027

Annual report '26

Regulatory press release5/28/2026, 7:59 AM

Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)

Isofol Medical
Regulatory press release5/26/2026, 11:24 AM

Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)

Isofol Medical
Regulatory press release5/22/2026, 8:50 AM

Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)

Isofol Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/21/2026, 8:31 AM

Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)

Isofol Medical
Regulatory press release5/19/2026, 2:45 PM

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

Isofol Medical
Regulatory press release5/19/2026, 2:45 PM

Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2026

Isofol Medical
Press release5/19/2026, 11:14 AM

Redeye: Isofol Medical (Q1 Review): Tailwind despite slower recruitment

Isofol Medical
Third party research5/19/2026, 7:38 AM

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Isofol Medical
Regulatory press release5/19/2026, 6:00 AM

Isofol Medical AB (publ) publicerar delårsrapport för januari – mars 2026

Isofol Medical
Regulatory press release5/19/2026, 6:00 AM

Isofol Medical AB (publ) publishes interim report, January – March 2026

Isofol Medical
Regulatory press release4/30/2026, 6:00 AM

Nytt antal aktier och röster i Isofol

Isofol Medical
Regulatory press release4/30/2026, 6:00 AM

New number of shares and votes in Isofol

Isofol Medical
Regulatory press release4/15/2026, 2:00 PM

Kallelse till årsstämma den 19 maj 2026 i Isofol Medical AB (publ)

Isofol Medical
Regulatory press release4/15/2026, 2:00 PM

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol Medical
Press release4/15/2026, 7:10 AM

Isofol optimerar designen av sin fas Ib/II-studie efter nytt regulatoriskt godkännande

Isofol Medical
Press release4/15/2026, 7:10 AM

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical
Regulatory press release4/10/2026, 7:50 AM

Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)

Isofol Medical
Regulatory press release4/10/2026, 6:00 AM

Isofol Medical AB (publ) offentliggör årsredovisning och bolagsstyrningsrapport för 2025

Isofol Medical
Regulatory press release4/10/2026, 6:00 AM

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Isofol Medical
Regulatory press release3/31/2026, 3:00 PM

Isofol erhåller bruttolikvid om 18,9 MSEK i samband med optionsinlösen och garantiåtagande för teckningsoptioner av serie TO1 samt beslutar om riktad nyemission

Isofol Medical